JPMorgan Upgrades Illumina to Overweight on Clinical Demand Outlook

JPMorgan upgraded Illumina (NASDAQ:ILMN) to Overweight from Neutral and raised its December 2026 price target to $185 from $125, according to a report from Investing.com.

Rating Change

Previously, JPMorgan rated Illumina as Neutral with a $125 price target. The new rating is Overweight with a $185 price target, reflecting an approximately 48% increase from the previous target.

Analyst Rationale

JPMorgan analysts cited growing confidence in Illumina's ability to maintain strong growth despite increasing competition in the DNA sequencing market. The bank highlighted rising clinical demand as a key driver, as sequencing expands into diagnostics and precision medicine.

Context

The upgrade comes amid competition from Pacific Biosciences and Oxford Nanopore. However, JPMorgan believes Illumina's entrenched position in the clinical market provides a competitive edge. No other analysts have issued similar comments yet.

Conclusion

The upgrade reflects a positive outlook from JPMorgan, but investors should consider competitive risks and current valuation before making decisions.